DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

VERAXA Biotech AG ( VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

OBI Pharma has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) ...

Concerns around the proposed US Biosecure Act, lingering trade tensions, and the spectre of potential US tariffs are ...

Market pessimism has undervalued Pfizer and Rexford, both offering high yields and overlooked growth potential. Learn more on ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

DCx will gain rights to technology, targets, and preclinical programs from Repare along with lab space and staff in Montreal.

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...